Stocks · News reference
Filed: 2026-08-03 AccNo: 0001193125-26-330730 Size: 147 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Cue Biopharma (NASDAQ:CUE) reported quarterly losses of $(24.14) per share which missed the analyst consensus estimate of $(1.69) by 1328.4 percent. This is a 794.07 percent decrease over losses of $(2.70) per share
Read original at benzingaFiled: 2026-08-14 AccNo: 0001193125-26-352126 Size: 413 KB Item 2.02: Results of Operations and Financial Condition
Read original at edgarhttps://www.sec.gov/Archives/edgar/data/1645460/000119312526346867/d136967ds3.htm
Read original at benzingaCue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company targeting transformative therapies for immune-mediated diseases, today announced the appointment of James M. Ahlers as Chief Financial
Read original at benzinga